Trial Profile
Identification of Biomarkers for Prediction of Hepatocellular Carcinoma after Elimination of Hepatitis C Virus by Antiviral Medicines, mavilet
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2018
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Biomarker; Pharmacodynamics
- 06 Feb 2018 New trial record